J
John A. Dormandy
Researcher at St George's Hospital
Publications - 103
Citations - 20013
John A. Dormandy is an academic researcher from St George's Hospital. The author has contributed to research in topics: Population & Pioglitazone. The author has an hindex of 42, co-authored 103 publications receiving 18635 citations.
Papers
More filters
Journal ArticleDOI
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
Lars Norgren,William R. Hiatt,John A. Dormandy,Mark R. Nehler,Kenneth A. Harris,F. G. R. Fowkes +5 more
TL;DR: The goals of this new consensus are to provide an abbreviated document to focus on key aspects of diagnosis and management, and to update the information based on new publications and the newer guidelines, but not to add an extensive list of references.
Journal ArticleDOI
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
John A. Dormandy,Bernard Charbonnel,David Eckland,Erland Erdmann,Massimo Massi-Benedetti,Ian K. Moules,Allan M. Skene,Meng H. Tan,P. J. Lefebvre,Gordon D Murray,Eberhard Standl,Robert G. Wilcox,Lars Wilhelmsen,John Betteridge,Kåre I. Birkeland,Alain Golay,Robert J. Heine,László Korányi,Markku Laakso,Marián Mokáň,Antanas Norkus,Valdis Pirags,Toomas Podar,André Scheen,Werner A. Scherbaum,Guntram Schernthaner,Ole Schmitz,Jan Škrha,Ulf Smith,Jan Tatoň +29 more
TL;DR: Overall safety and tolerability was good with no change in the safety profile of pioglitazone identified; mortality rates from heart failure did not differ between groups.
Journal Article
Inter-society consensus for the management of peripheral arterial disease
Lars Norgren,William R. Hiatt,John A. Dormandy,Mark R. Nehler,Kenneth A. Harris,F. G. R. Fowkes,Robert B. Rutherford +6 more
Journal ArticleDOI
Causes of venous ulceration: a new hypothesis
TL;DR: A new hypothesis linking these two findings proposes that the trapped while cells occlude the capillaries and result in ischaemia of the skin of the leg.
Journal ArticleDOI
Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke Results From PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)
Robert G. Wilcox,Marie-Germaine Bousser,D. John Betteridge,Guntram Schernthaner,Valdis Pirags,Stuart Kupfer,John A. Dormandy +6 more
TL;DR: In a subgroup analysis from PROactive, pioglitazone reduced the risk of recurrent stroke significantly in high-risk patients with type 2 diabetes.